Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Cerevel Therapeutics Holdings Inc (CERE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cerevel Therapeutics Holdings's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
42.55 -0.04    -0.09%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
42.61
+0.06
+0.15%
22:47:00 - Real-time Data
  • Volume: 907,408
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 42.54 - 42.79
Type:  Equity
Market:  United States
Cerevel Therapeutics Holdings 42.55 -0.04 -0.09%

Cerevel Therapeutics Holdings Company Profile

 
Read the Cerevel Therapeutics Holdings Inc company profile to learn more about the business and the management team. View Cerevel Therapeutics Holdings Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

321

Equity Type

ORD

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 222 Jacobs Street Suite 200
Cambridge, 02141
United States
Phone 844 304 2048
Fax -

Top Executives

Name Age Since Title
Gabrielle E. Greene-Sulzberger 63 2019 Independent Director
Norbert G. Riedel 65 2018 Lead Independent Director
Adam M. Koppel 53 2018 Independent Director
Ruth McKernan 65 2020 Independent Director
N. Anthony Coles 63 2018 Executive Chairman
Deval L. Patrick 66 2021 Independent Director
Deborah Baron 53 2021 Independent Director
Christopher Riley Gordon 50 2018 Independent Director
Suneet Varma - 2022 Independent Director
Douglas E. Giordano 61 2018 Independent Director
Marijn E. Dekkers 66 2018 Independent Director
Ronald C. Renaud 55 2023 President, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CERE Price Commentary

Write your thoughts about Cerevel Therapeutics Holdings Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Zawareh Khandhadia
Zawareh Khandhadia Jun 29, 2021 20:05
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bullish now but skeptical 🤔🤔🤔🤔
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email